Xenon to Report Q3 2024 Financial Results on November 12, 2024

Rhea-AI Summary

Xenon Pharmaceuticals (Nasdaq: XENE) has announced it will report its third quarter 2024 financial results after U.S. market close on Tuesday, November 12, 2024. The company will host a conference call and webcast at 4:30 pm Eastern Time on the same day. Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.

VANCOUVER, British Columbia and BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its third quarter 2024 financial results after the close of U.S. financial markets on Tuesday, November 12, 2024.

Conference Call/Webcast Information:

Date:	Tuesday, November 12, 2024
Time:	4:30 pm Eastern Time (1:30 pm Pacific Time)
Webcast:	Pre-register here
Dial-In:	(800) 715-9871 toll-free or (646) 307-1963 for international callers
Conference ID:	7128308

A live webcast of the company presentation will be available on the “Investors” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com

For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com

FAQ

When will Xenon Pharmaceuticals (XENE) report Q3 2024 earnings?

Xenon Pharmaceuticals will report its Q3 2024 financial results after U.S. market close on Tuesday, November 12, 2024.

What time is Xenon's (XENE) Q3 2024 earnings call?

Xenon's Q3 2024 earnings conference call is scheduled for Tuesday, November 12, 2024, at 4:30 pm Eastern Time (1:30 pm Pacific Time).

What is Xenon's (XENE) main drug candidate?

Xenon's lead drug candidate is azetukalner, a novel Kv7 potassium channel opener in late-stage clinical development for multiple indications.

What therapeutic areas does Xenon (XENE) focus on?

Xenon focuses on neuroscience, specifically developing treatments for epilepsy and depression through their ion channel product portfolio.